Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Scher

Showing results (411-420 of 692) with videos related to

Pageof 70
Sort By:
The Lancet. Neurology|May 22, 2021
Post-traumatic headache attributed to traumatic brain injury: classification, clinical characteristics, and treatmentHåkan Ashina, Anna K Eigenbrodt, Tad Seifert, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|February 22, 2005
Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancerMichael J Morris, Carlos Cordon-Cardo, William K Kelly, et al.
International Journal of Radiation Oncology, Biology, Physics|October 1, 1991
Twice daily thoracic irradiation for limited small cell lung cancerJ G Armstrong, M M Rosenstein, M G Kris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1994
Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-upP K Schultz, H W Herr, Z F Zhang, et al.
The Journal of Urology|March 1, 1985
Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urotheliumC N Sternberg, A Yagoda, H I Scher, et al.
Cancer|December 15, 1989
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapseC N Sternberg, A Yagoda, H I Scher, et al.
The Journal of Urology|March 1, 1988
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesionH I Scher, A Yagoda, H W Herr, et al.
Clinical Genitourinary Cancer|December 14, 2021
Correlation Between Imaging-Based Intermediate Endpoints and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria in 16,511 PatientsSungmin Woo, Chong Hyun Suh, Andreas G Wibmer, et al.
European Urology|August 2, 2011
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetateDaniel C Danila, Aseem Anand, Clifford C Sung, et al.
International Journal of Cancer|November 13, 2008
Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomySven Wenske, Ruslan Korets, Angel M Cronin, et al.
Pageof 70

Showing results (411-420 of 692) with videos related to

Sort By:
Pageof 70
The Lancet. Neurology|May 22, 2021
Post-traumatic headache attributed to traumatic brain injury: classification, clinical characteristics, and treatmentHåkan Ashina, Anna K Eigenbrodt, Tad Seifert, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|February 22, 2005
Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancerMichael J Morris, Carlos Cordon-Cardo, William K Kelly, et al.
International Journal of Radiation Oncology, Biology, Physics|October 1, 1991
Twice daily thoracic irradiation for limited small cell lung cancerJ G Armstrong, M M Rosenstein, M G Kris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1994
Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-upP K Schultz, H W Herr, Z F Zhang, et al.
The Journal of Urology|March 1, 1985
Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urotheliumC N Sternberg, A Yagoda, H I Scher, et al.
Cancer|December 15, 1989
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapseC N Sternberg, A Yagoda, H I Scher, et al.
The Journal of Urology|March 1, 1988
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesionH I Scher, A Yagoda, H W Herr, et al.
Clinical Genitourinary Cancer|December 14, 2021
Correlation Between Imaging-Based Intermediate Endpoints and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria in 16,511 PatientsSungmin Woo, Chong Hyun Suh, Andreas G Wibmer, et al.
European Urology|August 2, 2011
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetateDaniel C Danila, Aseem Anand, Clifford C Sung, et al.
International Journal of Cancer|November 13, 2008
Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomySven Wenske, Ruslan Korets, Angel M Cronin, et al.
Pageof 70